Testing BI 3819026 Alone and With Ezabenlimab for Advanced Cancer
Treatments studied
Part of Cancer clinical trials.
This early-stage study tests whether a new drug called BI 3819026, alone or combined with another drug called ezabenlimab, is safe and well-tolerated in people whose advanced solid tumors have stopped responding to standard treatments. The goal is to find the right dose and understand how the drugs work in your body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid cancer (cancer that has spread) that either isn't responding to standard treatments or you've exhausted available options
- Your cancer can be measured on imaging and you have at least one lesion outside the brain
- If you have brain tumors, they must be stable and treated, with treatment completed at least 2–4 weeks ago, and you're not on steroids or seizure medications
- Side effects from your previous cancer treatments have resolved to mild levels or returned to baseline
- Your liver, kidney, and bone marrow function are adequate
- You haven't had cancer treatments (chemotherapy or other drugs) within the past 3 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational drug called BI 3968621, given either by itself or with another drug called ezabenlimab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe and effective doses and see if the combination helps shrink tumors or slow their growth.
This Phase 1 trial tests how different doses of a study drug (BI 1703880) work and how safe they are when given with ezabenlimab for advanced solid tumors. It’s for people whose cancer can’t be removed with surgery and who have tried standard treatments or can’t get them.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
This trial tests a new drug called BI 3810944 for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the drug is safe and helps shrink tumors.
This study tests a new drug, BI 4060107, in people with advanced solid tumors. It is a phase 1 trial to find a safe dose and see how well people tolerate it, potentially offering a new option when standard treatments have stopped working.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.